Welcome to the Empowered Patient Podcast with Karen Jagoda. This show is a window into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the changing dynamics in the medical and healthcare environment. One focus is on how providers, pharmaceutical companies, and payers are empowering patients. In addition, conversations are often about how providers, care facilities, pharmaceutical companies, and payers are being empowered by technology to improve patient outcomes and reduce friction across the healthcare landscape.
Popular Topics
- Virtual and digital health
- Use of AI, ML, and LLM in healthcare and drug discovery, development, trials
- Value-based healthcare
- Precision and stratified medicine
- Integration of digital technology into existing workflow and procedures
- Next-generation immuno, cell, and gene therapies
- Vaccines
- Biomarkers, sequencing, and imaging
- Rare diseases
- MedTech and medical devices
- Clinical trials
- Addressing Social Determinants of Health
- Treating chronic conditions like obesity and pain
- Clinician and staff burnout
The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.
Check out our new EmpoweredPatient.Solutions site where you can quickly search all of the Empowered Patient Podcast interviews by any word or phrase to identify useful resources, potential partners, and insights about the life sciences landscape.
Modifying Macrophages to Overcome Evasion by Cancer Cells and Educate Immune System with Robert Towarnicki SIRPant Immunotherapeutics TRANSCRIPT
Download PDFMay 23, 2024
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPĪ±...
May 23, 2024
Robert Towarnicki, CEO and Co-founder of SIRPant Immunotherapeutics, discusses cancer-specific immunotherapy for aggressive tumors, the role macrophages play in the immune response to cancer, and how cancer cells can shut down this response. SIRPant Immunotherapeutics aims to modify macrophages by reducing SIRPĪ±...
Next-Generation T-Cell Therapy Recognizes Multiple Antigens Fights Tumor Resistance with Dr. Juan Vera Marker Therapeutics TRANSCRIPT
Download PDFNov 21, 2023
Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company, is developing next-generation immunotherapy with a multi-tumor-specific T-cell platform to overcome limitations of current T-cell therapies with narrow target recognition. This approach, which recognizes multiple antigens within the...
Nov 21, 2023
Dr. Juan Vera, CEO of Marker Therapeutics, a clinical-stage immuno-oncology company, is developing next-generation immunotherapy with a multi-tumor-specific T-cell platform to overcome limitations of current T-cell therapies with narrow target recognition. This approach, which recognizes multiple antigens within the...
Approved Immunotherapy for Endometrial Cancer with Dr. Matthew Powell Washington University TRANSCRIPT
Download PDFSep 23, 2023
Dr. Matthew Powell, professor of obstetrics and gynecology and Chief of the Gynecological Oncology Division at Washington University. He was also a clinical investigator in the pivotal trial leading to the approval of Jemperli, a treatment for endometrial cancer. This is an immunotherapy drug that works well for...